key: cord-0852731-wnmxkg30
authors: Jiménez‐Alcaide, Estíbaliz; García‐Fuentes, Clara; Hernández, Virginia; De la Peña, Enrique; Pérez‐Fernández, Elia; Castro, Alejandro; Caballero‐Perea, Begoña; Guijarro, Ana; Llorente, Carlos
title: Influence of androgen deprivation therapy on the severity of COVID‐19 in prostate cancer patients
date: 2021-09-13
journal: Prostate
DOI: 10.1002/pros.24232
sha: 141bd534d02a7c38d5468fd0724ce885cc752443
doc_id: 852731
cord_uid: wnmxkg30

BACKGROUND: The TMPRSS2 protein has been involved in severe acute respiratory syndrome caused by coronavirus 2 (SARS‐CoV‐2). The production is regulated by the androgen receptor (AR). It is speculated that androgen deprivation therapy (ADT) may protect patients affected by prostate cancer (PC) from SARS‐CoV‐2 infection. METHODS: This is a retrospective study of patients treated for COVID‐19 in our institution who had a previous diagnosis of PC. We analyzed the influence of exposure of ADT on the presence of severe course of COVID‐19. RESULTS: A total of 2280 patients were treated in our center for COVID‐19 with a worse course of disease in males (higher rates of hospitalization, intense care unit [ICU] admission, and death). Out of 1349 subjects registered in our PC database, 156 were on ADT and 1193 were not. Out of those, 61 (4.52%) PC patients suffered from COVID‐19, 11 (18.0%) belonged to the ADT group, and 50 (82.0%) to the non‐ADT group. Regarding the influence of ADT on the course of the disease, statistically significant differences were found neither in the death rate (27.3% vs. 34%; p = 0.481), nor in the presence of severe COVID‐19: need for intubation or ICU admission (0% vs. 6.3%; p = 0.561) and need for corticoid treatment, interferon beta, or tocilizumab (60% vs. 34.7%; p = 0.128). Multivariate analysis adjusted for clinically relevant comorbidities did not find that ADT was a protective factor for worse clinical evolution (risk ratio [RR] 1.08; 95% confidence interval [CI], 0.64–1.83; p = 0.77) or death (RR, 0.67; 95% CI, 0.26–1.74; p = 0.41). CONCLUSIONS: Our study confirms that COVID‐19 is more severe in men. However, the use of ADT in patients with PC was not shown to prevent the risk of severe COVID‐19.

In late 2019, a new human coronavirus (SARS-CoV-2) causing severe acute respiratory syndrome (SARS) [1] [2] [3] 

Wuhan, China. SARS-CoV-2 causes a broad spectrum of diseases that are included under the term COVID-19 (coronavirus disease 2019) ranging from moderate respiratory infection to severe pneumonia, multiorgan failure, and even death. 4 As of February 2021, SARS-CoV-2 has spread to 192 countries with more than 107 million people infected and causing more than 2.3 million deaths worldwide. 5 The different pathophysiological mechanisms involved in cell entry causing COVID-19 are currently being studied. [6] [7] [8] The transmembrane serine protease 2 (TMPRSS2) has been found to be involved as a critical host cell factor for the spread of several clinically relevant viruses including SARS-CoV-2. 9 TMPRSS2 protein production is regulated by the androgen receptor (AR), which is an important molecular driver of both localized and metastatic prostate cancer (PC). [10] [11] [12] Interestingly, AR has been demonstrated in vitro to regulate TMPRSS2 expression also, in nonprostatic tissues, including the lung. In tests carried out in vitro in murine lung, it has been proven that androgen deprivation therapy (ADT) acts by reducing the transcription of TMPRSS2. 13 That may explain the increased susceptibility of men to develop severe SARS-CoV-2 infections.

For all the above reasons, we hypothesized that in patients with PC, ADT could act as a protective factor, given that TMPRSS2 levels are under the control of androgens not only in the prostate but also in the lung.

Therefore, the aim of this study was to determine the incidence and the severity of SARS-CoV-2 infection in patients with PC and to analyze the influence of ADT use in the disease.

We conducted a review of all the patients who visited our center between March 15 and May 15, 2020 with SARS-CoV-2 infection. Of all the patients attended during the study period, we selected those who were also previously diagnosed with PC. For this purpose, data from two institutional databases of patients treated with COVID-19, and of those under treatment or follow-up for PC were cross-referenced.

Polymerase chain reaction (PCR) was carried out on all those patients presenting symptoms suggestive of the disease at the emergency department. In those patients who presented with clinical/radiological disease consistent with COVID-19 and with negative PCR, the test was repeated by extracting a bronchial lavage sample, as this was considered to be more cost-effective. In case of continuing negative results, with high clinical suspicion, patients were considered and treated in the same way as patients who had microbiological confirmation.

For the analysis, we divided the patients with a previous diagnosis of PC and SARS-CoV-2 infection into two groups: one including those under active treatment with ADT or treated during the year before the diagnosis of SARS-CoV-2 infection, and another group of subjects with PC not treated with ADT.

First of all, demographic characteristics of both groups of patients were analyzed including age and comorbidity measured according to the Charlson Index, as well as data related to PC: prostate-specific antigen (PSA), tumor-node-metastases (TNM) stage, Gleason grading system, and the primary treatment regime received at diagnosis (radical prostatectomy, radiotherapy, ADT, or watchful waiting with or without subsequent need for ADT during follow-up).

Variables considered relevant for SARS-CoV-2 pneumonia were examined: pulmonary diseases such as chronic obstructive pulmonary disease (COPD) and asthma and other relevant comorbidities not included in the Charlson Index (hypertension, tobacco smoking, obesity, and obstructive sleep apnea syndrome [OSAS]). 4 The presence of severe COVID-19 pneumonia was also analyzed.

Although most of the patients with this pathology meet a series of common characteristics (alteration of the pulmonary radiological pattern or treatment with certain drugs such as antibiotics, heparin and supplemental oxygen requirements), a set of criteria was selected to assess the severity of pneumonia:

(i) Need for intubation or intense unit care (ICU) admission.

(ii) Type of treatment received, considering the need for corticotherapy, 4 interferon beta, and tocilizumab 14 as indicators of greater severity.

(iii) Radiological pattern: Given the great variability of radiological patterns, was decided to group them into three classes: (a) extensive, multilobar, and/or bilateral involvement (estimated as the most severe disease presentation), (b) unilobar involvement, and (c) no radiological signs of pneumonia. 1, 4 Finally, the differences in mortality rates in both groups were analyzed.

The cumulative incidence of SARS-CoV-2 infection in PC patients was estimated and 95% confidence interval (95% CI) was calculated by considering Poisson distribution. 15 The distribution of quantitative data was presented by mean and SD or median and interquartile range and in the case of qualitative data was presented by absolute and relative frequencies.

To analyze if the hormonal treatment influenced the evolution of the disease (prognosis and mortality) in COVID-19 patients, a univariate analysis was first performed to determine the homogeneity of the two groups. We calculated the χ 2 test or Fisher's exact test for qualitative variables and the Student t test or the nonparametric Mann-Whitney U test for quantitative variables, according to data distribution.

As a treatment effect, the unadjusted relative risk was estimated and also adjusted for the heterogeneous variables between the two groups and clinically relevant variables (age, Charlson Comorbidity Index, hypertension, and obesity), using modified Poisson regression models (with robust standard errors).

All tests were considered bilateral and values of p < 0.05 were considered to be statistically significant.

The statistical analysis was performed using the SPSS (SPSS Inc. without finding statistically significant differences in any of the variables. Charlson Comorbidity Index score, COPD, and asthma were slightly higher in the group treated with ADT (Table 1) .

Statistically significant differences were found in the pathological characteristics of the tumor between groups. As expected, higher risk disease with a higher rate of metastasis was described in the ADT group ( Table 2) .

The mean testosterone level in the group of patients treated with hormone therapy was 0.14 ng/ml. In the ADT group, four patients treated with radiotherapy at diagnosis received ADT as part of a neo/ adjuvant treatment. In one patient, ADT was given during follow-up due to progression. Of the four patients treated with ADT at diagnosis, three were metastatic at baseline and two of them received abiraterone associated with ADT. Of these two patients, one of them eventually received chemotherapy treatment due to disease progression despite treatment with abiraterone.

The results about the influence of hormone therapy on the course of the disease are presented in Table 3 . No differences were found between groups either in the death rate or in the comparison of poor prognostic COVID-19 factors between groups.

Treatment with ADT was not found to be a protective factor for poor outcomes such as need for ICU, use of specific treatment (risk For these reasons, exposed above linking the androgen pathway to the regulation of TMPRSS2 expression, it has been hypothesized that androgen blockade by ADT treatment could ameliorate SARS-CoV-2 infection.

Regarding the relationship between the androgenic environment and SARS-CoV-2 infection, as well as its severity, we found that, in our series, there was a higher incidence of SARS-CoV-2 infection in men (55.82%) than in women (44.18%). In addition, men had a higher rate of hospitalization (79.4% vs. 73.8%; p = 0.015), of ICU admissions (9.2% vs. 5.3%; p = 0.007), and a higher death rate (21.3% vs. 12.9%; p < 0.001). 19 Our which would support the theories previously mentioned. CoV-2 infection than the hormonal influence. Therefore, this association should be taken with caution and verified or rejected by large prospective studies with longer follow-up.

In this regard, there are two ongoing trials, evaluating the role of 5-alpha-reductase inhibitors, dutasteride 24 and proxalutamide, 25 in the severity of COVID-19, both with pending results.

Our study confirms that COVID-19 is more severe in men. However, the use of ADT in patients with PC was not shown to prevent the risk of severe COVID-19. Our findings do not support the positive results of this association published by other series, and it will be necessary to develop clinical trials to assess if ADT could be added in the therapeutic arsenal against SARS-CoV-2 infection. Abbreviations: ADT, androgen deprivation therapy; CI, confidence interval; ICU, intensive care unit; RR, risk ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A novel coronavirus from patients with pneumonia in China

Clinical characteristics of coronavirus disease 2019 in China

Johns Hopkins Coronavirus Resource Center. COVID-19 Map

Type II transmembrane serine proteases as potential target for anti-influenza drug discovery

Type II transmembrane serine proteases in cancer and viral infections

Type II transmembrane serine proteases

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

The early effects of rapid androgen deprivation on human prostate cancer

The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis

The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma

Androgen receptor and androgen-dependent gene expression in lung

Current status of potential therapeutic candidates for the COVID-19 crisis

A modified Poisson regression approach to prospective studies with binary data

The early effects of rapid androgen deprivation on human prostate cancer

Sex differences in immune responses

Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade

Sex difference and smoking predisposition in patients with COVID-19

Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a populationbased study (N = 4532)

Androgen deprivation therapy in men with prostate cancer does not affect risk of infection with SARS-CoV-2

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2

Does androgen deprivation therapy protect against severe complications from COVID-19?

Identifier NCT 04729491, Early Antiandrogen Treatment (EAT) With Dutasteride for COVID-19 (EAT-DUTA AndroCoV Trial

Bethesda (MD): National Library of Medicine (US)

How to cite this article

Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients

The authors declare that there are no conflict of interests.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Estíbaliz Jiménez-Alcaide https://orcid.org/0000-0002-0941-1485